Newsroom

Healthcare Pharmaceutical Biotech

Stay informed with the latest in Healthcare, Pharmaceutical and Biotech press releases through our newsroom. Explore breaking updates, industry trends, and insights shaping these vital sectors—all in one place. Whether it’s innovation, regulatory changes, or breakthroughs, our newsroom keeps you connected to the stories that matter most.

All News

IRLAB publishes the Annual Report for 2024
Healthcare & PharmaceuticalEarnings

IRLAB publishes the Annual Report for 2024

April 25, 2025 4:00 PM

IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - Gothenburg, Sweden, April 25, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, announced today that the Annual Report for 2024 is published on the company's website, www.irlab.se.IRLAB has published the Annual Report 2024 for the financial year, which covers January 1 to December 31, 2024. The Annual Report is...

Read more
Cantargia Presents Association Between Nadunolimab and Reduction of Chemotherapy Induced Peripheral Neuropathy (CIPN) at AACR
Healthcare & PharmaceuticalCompany Update

Cantargia Presents Association Between Nadunolimab and Reduction of Chemotherapy Induced Peripheral Neuropathy (CIPN) at AACR

April 25, 2025 1:15 PM

Cantargia (STO:CANTA)Clinical findings show association between nadunolimab and lower incidence and later onset of CIPNPreclinical data show prevention of both chemotherapy- and antibody-drug conjugate- (ADC) payload-induced neuropathy by a nadunolimab surrogate, supporting the clinical observations and suggesting an extension of benefits into the ADC fieldCantargia (Cantargia AB (publ); Nasdaq Stockholm: CANTA) today released a poster on...

Read more
Cantargia Presents Promising Preclinical Results on Anti-IL1RAP Antibody-Drug Conjugate (ADC) at a Major Cancer Conference
Healthcare & PharmaceuticalCompany Update

Cantargia Presents Promising Preclinical Results on Anti-IL1RAP Antibody-Drug Conjugate (ADC) at a Major Cancer Conference

April 25, 2025 1:15 PM

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today released a poster with new preclinical data that strengthens the rationale behind the development of novel anti-IL1RAP ADCs. The current study shows the potential of interleukin-1 receptor accessory protein (IL1RAP) as a target for ADC therapy across a broad spectrum of cancers.The poster is presented at the American Association for Cancer Research (AACR) Annual Meeting."IL1RAP is an...

Read more
Robotic Process Automation Transforms Healthcare RCM: 2025 Survey Highlights From Black Book
Healthcare & PharmaceuticalCompany Update

Robotic Process Automation Transforms Healthcare RCM: 2025 Survey Highlights From Black Book

April 25, 2025 9:00 AM

As U.S. healthcare organizations confront intensifying financial pressures, staffing constraints, and escalating administrative workloads, Robotic Process Automation (RPA) has emerged as a cornerstone of sustainable revenue cycle transformation. Today, Black Book Research-a leading independent source for global healthcare IT insights-released its 2025 report: Robotic Process Automation in Healthcare Revenue Cycle Management: Strategic Outlook...

Read more
Cipher Surgical Completes $10 Million Series A Funding Round
Healthcare & PharmaceuticalFinancing

Cipher Surgical Completes $10 Million Series A Funding Round

April 25, 2025 9:00 AM

Cipher Surgical, a leading innovator in laparoscopic surgical technology, today announced the successful completion of a $10 million Series A funding round. The investment was led by Medical Solutions, Inc., a global leader in medical device investment and innovation.This funding round marks a significant milestone for Cipher Surgical, enabling the company to accelerate commercialization of its patented OpClear® technology, expand into new...

Read more
Bulletin from Annual General Meeting in XVIVO Perfusion AB (publ)
Healthcare & PharmaceuticalShareholder Meeting

Bulletin from Annual General Meeting in XVIVO Perfusion AB (publ)

April 25, 2025 8:30 AM

GOTHENBURG, SWEDEN / ACCESS Newswire / April 25, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)The following resolutions were passed at the Annual General Meeting (the "AGM") of XVIVO Perfusion AB (publ) ("XVIVO Perfusion" or the "Company") held today on 25 April 2025 in Gothenburg, Sweden.Adoption of Income Statement and Balance Sheet for the Financial Year 2024 and Discharge from LiabilityThe AGM resolved to adopt the income...

Read more
Bausch Health Announces Launch of Solta Medical's Fraxel FTX(TM)
Healthcare & PharmaceuticalProduct Announcements

Bausch Health Announces Launch of Solta Medical's Fraxel FTX(TM)

April 25, 2025 8:00 AM

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its aesthetics business, Solta Medical, announced today Fraxel FTX™ will launch at the American Society for Laser Medicine & Surgery, Inc. (ASLMS) 2025 Annual Conference on April 25 in Orlando, FL. This event begins the rollout of Fraxel FTX™ to dermatologists, plastic surgeons, and other licensed aesthetic professionals across the United States,...

Read more
Reproductive Health Supplements from Ovaterra at the Cutting Edge of Fertility Support
Healthcare & PharmaceuticalProduct Announcements

Reproductive Health Supplements from Ovaterra at the Cutting Edge of Fertility Support

April 25, 2025 8:00 AM

Ovaterra, a maker of reproductive and sexual health supplements based out of New York City, is on a mission to produce the most advanced and effective preconception and prenatal vitamins. Backed by the scientific research of Dr. Norbert Gleicher, MD, FACOG, FACS, Ovaterra develops nutritional supplements that support fertility as part of a balanced diet and lifestyle, offering cutting-edge solutions for both women and men that stand out for...

Read more
iZafe Group Q1 Interim Report, January-March 2025
Healthcare & PharmaceuticalEarnings

iZafe Group Q1 Interim Report, January-March 2025

April 25, 2025 2:50 AM

iZafe Group (STO:IZAFE-B) - iZafe Group AB (publ.) presents today, April 25th, its report for the first quarter.Financial Performance in SummaryTotal net revenue for the quarter amounted to 1,318 TSEK (3,410), now primarily consisting of recurring license revenues. This contrasts with the same period last year, when revenue was mainly driven by hardware sales, which in turn enable the generation of these recurring license revenues.Operating...

Read more
Onco-Innovations' Inka Health Signs New Analytical Work with AstraZeneca Canada to Advance Real-World Evidence in Regulatory Science
Healthcare & PharmaceuticalCompany Update

Onco-Innovations' Inka Health Signs New Analytical Work with AstraZeneca Canada to Advance Real-World Evidence in Regulatory Science

April 24, 2025 6:00 PM

Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly owned subsidiary, Inka Health Corp. ("Inka Health"), signed a new analytical work contract[1] with AstraZeneca Canada ("AstraZeneca") on March 20, 2025 to support the next phase of real-world evidence (RWE) research and scientific dissemination. The Company perceives this renewed engagement as a meaningful...

Read more
Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds
Healthcare & PharmaceuticalCompany Update

Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

April 24, 2025 4:15 PM

Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the closing of its previously announced exercise of certain outstanding warrants to purchase up to an aggregate of 630,376 shares of common stock of the Company originally issued in March 2025, having an exercise price of...

Read more
Sales and Marketing Rights of Gleolan(R) (Aminolevulinic Acid HCl) Return to NX Development Corp.
Healthcare & PharmaceuticalCompany Update

Sales and Marketing Rights of Gleolan(R) (Aminolevulinic Acid HCl) Return to NX Development Corp.

April 24, 2025 2:00 PM

Today, NX Development Corp ("NXDC"), a Lexington, KY based life sciences company, announced the return of the sales and marketing rights for Gleolan® (aminolevulinic acid HCl) from Medexus Pharmaceuticals. As the company that first launched the product in 2017, NXDC has held the marketing authorization for Gleolan for the past 7 years. Moving forward, they are now also responsible for selling and marketing the product under the NXDC brand."We...

Read more
Travel Nurses, Inc. Wins Culture Excellence Award
Healthcare & PharmaceuticalAwards

Travel Nurses, Inc. Wins Culture Excellence Award

April 24, 2025 11:00 AM

Travel Nurses, Inc. is proud to announce that it was named a 2025 Top Workplaces Culture Excellence winner by Energage. This national recognition highlights excellence in several key areas, including Innovation, Work-Life Flexibility, Compensation & Benefits, Leadership, and Purpose & Values.Travel Nurses, Inc. was recognized for fostering a culture where new ideas are encouraged from all levels, supporting employees through flexible work...

Read more
SFWJ/MedCana Announces Another Large Reduction to its Outstanding Shares
Healthcare & PharmaceuticalCompany Update

SFWJ/MedCana Announces Another Large Reduction to its Outstanding Shares

April 24, 2025 10:40 AM

Software Effective Solutions Corp. (OTC PINK:SFWJ), doing business as MedCana, is canceling 16,193,760 million shares and swapping 72,750,081 million shares of its Common stock.All 88,943,841 shares will show a reduction in the outstanding share count. The 72,750,081 million shares will be swapped for a Preferred share, allowing the holder to convert back to Common stock in 12 months from the issuance date.The Company is working to reduce the...

Read more
San Diego-Based Shoreline Recovery Center Addresses How Childhood Trauma Fuels the Cycle of Addiction
Healthcare & PharmaceuticalCompany Update

San Diego-Based Shoreline Recovery Center Addresses How Childhood Trauma Fuels the Cycle of Addiction

April 24, 2025 10:00 AM

Childhood trauma is a powerful predictor of substance misuse and addiction in adulthood. Many individuals who experienced abuse or neglect early in life turn to drugs or alcohol as an adult to self-medicate. Shoreline Recovery Center specializes in mental health, individual drug and alcohol treatment plans and strategic aftercare. Its team of highly credentialed addiction doctors, therapists, counselors and mentors coach clients through a blend...

Read more
Ivy en Rose MedSpa and the Junior League of San Francisco Announce New Date for Their Partnered Event, to Be Held on May 20, 2025
Healthcare & PharmaceuticalCompany Update

Ivy en Rose MedSpa and the Junior League of San Francisco Announce New Date for Their Partnered Event, to Be Held on May 20, 2025

April 24, 2025 10:00 AM

Ivy En Rose, San Francisco's premier elite MedSpa, is proud to announce an exciting partnership with the Junior League of San Francisco for an exclusive community event that champions women's empowerment, beauty, and well-being. Now taking place on May 20th, 2025, at Ivy En Rose's new state-of-the-art facility located at 323 West Portal Ave., this event is a testament to the power of women-led businesses coming together to uplift their...

Read more
Senzime Publishes Annual and Sustainability Report for 2024
Healthcare & PharmaceuticalEarnings

Senzime Publishes Annual and Sustainability Report for 2024

April 24, 2025 9:45 AM

Senzime (STO:SEZI)(OTCQX:SNZZF) announces today that the company's annual and sustainability report for 2024 is published and available at the website www.senzime.com"2024 was a year of high growth, successful product launches, publication of favorable clinical studies, and continued commercial expansion.", commented Philip Siberg, CEO of SenzimeFor further information, please contact:Philip Siberg, CEO of Senzime ABPhone: +46 (0) 707 90 67 34,...

Read more
Global Interoperability Gaps Revealed in 2025 Healthcare Connectivity Rankings - Black Book
Healthcare & PharmaceuticalCompany Update

Global Interoperability Gaps Revealed in 2025 Healthcare Connectivity Rankings - Black Book

April 24, 2025 9:45 AM

A newly released international research by Black Book ranks the digital interoperability performance of healthcare systems worldwide, spotlighting major disparities in health data exchange capabilities and system integration across 18 high-income countries. The study-based on verified usage data, government platform metrics, and over 2 million stakeholder surveys-highlights Estonia as the global benchmark in EHR connectivity, achieving a 99.1%...

Read more
The Ridge RTC Announces Partnership With Avian Haven
Healthcare & PharmaceuticalCompany Update

The Ridge RTC Announces Partnership With Avian Haven

April 24, 2025 9:00 AM

The Ridge RTC is thrilled to announce a new partnership with Avian Haven, one of New England's largest wildlife rehabilitation organizations. Under the new partnership, Avian Haven will have access to the more than 400 acres of stunning natural landscape surrounding the Ridge RTC Maine, providing a perfect sanctuary for wild birds in need. These efforts are part of Ridge RTC's larger commitment to community health and wellness and mirror the...

Read more
Waymark Announces Partnership With Sentara Health Plans to Improve Medicaid Care Delivery in Virginia
Healthcare & PharmaceuticalPartnerships

Waymark Announces Partnership With Sentara Health Plans to Improve Medicaid Care Delivery in Virginia

April 24, 2025 9:00 AM

Waymark today announced a new value-based partnership with Sentara Health Plans, the health plan division of Sentara Health, aimed at transforming care delivery for Medicaid members. The collaboration will leverage Waymark's advanced data science technologies and community-based care teams to improve outcomes for Sentara Health Plans' Medicaid members in Hampton Roads and Richmond.Waymark's local teams of community health workers (CHWs),...

Read more

Join the thousands of ACCESS Newswire customers today who are getting millions of views on their news.


Check out our flexible subscription and pay as you go pricing

and packages.

Use Code NEWS10 for 10% off  of your first purchase.


Latest Blog Posts

Visit our blogs for press release tips, media engagement

Strategies, and Product Comparisons.

Executive delivering prepared remarks from an earnings call script
By Jennifer Hammers July 9, 2026
How to write earnings call prepared remarks that land — structure, length, the safe-harbor open, non-GAAP language, and building remarks around your strategy.
IR
By Brian Balbirnie July 8, 2026
A practical earnings call preparation checklist for IR teams — the two-week runway, consensus, logistics, Q&A prep, and Reg FD-clean disclosure timing.
ACCESS Newswire guide on AI investor relations — how AI assistants read company earnings disclosures
By Jennifer Hammers July 6, 2026
AI assistants read your earnings within minutes. Learn how IR teams make disclosures AI-readable — and how the LLM Citation Score measures your visibility.
What does Meltwater cost in 2026, and what are the alternatives? Meltwater resells press release dis
By Jennifer Hammers June 22, 2026
What does Meltwater cost in 2026, and what are the alternatives? See how ACCESS Newswire compares on distribution, data, and price.
A logo for accesswire next to a logo for rack
By Jennifer Hammers June 21, 2026
Compare Muck Rack vs ACCESS Newswire on pricing, features, and alternatives. See how ACCESS Newswire adds distribution, pitching, and analytics.
A blue and white logo with a check mark next to it
By Jennifer Hammers June 19, 2026
Compare Business Wire vs ACCESS Newswire on pricing and capabilities — and how ACCESS delivers comparable reach at a fraction of the cost.
Show More




Discover the news
by Industry:


Need help with your PR Strategy?
Learn more about our
professional PR Services today:

.MEDIA PRO 
Want to get noticed
by the Media but don’t
know how? 

.TOTAL PRO

Need full support to 

Optimize your PR

Efforts?